Literature DB >> 16316357

Progressive accumulation of lanthanum in the liver of normal and uremic rats.

Eduardo Slatopolsky1, Helen Liapis, Jane Finch.   

Abstract

BACKGROUND: The loss of renal function in chronic kidney disease (CKD) patients leads to a variety of metabolic disturbances that promote the development of secondary hyperparathyroidism (SH) and bone disease. One of these alterations, hyperphosphatemia, is a persistent problem in patients with CKD and is an important factor in the development and severity of SH as well as coronary artery and cardiac valve calcification. To help control serum phosphorus (P), phosphate binders are used to minimize intestinal absorption of P in these patients. Since the use of aluminum- and calcium-based phosphate binders can result in severe side effects, other phosphate binders have been proposed. One of these is lanthanum (La) carbonate.
METHODS: Since there is some controversy as to the degree La is absorbed by the intestine, whether it is deposited in tissues, and what effect its prolonged use would have in patients with chronic renal failure, we studied normal and uremic rats fed a control diet or a diet with La carbonate (1.5% elemental La) for 45, 90, or 110 days.
RESULTS: As expected, plasma creatinine increased after the induction of uremia and continued to increase with time. At 45 and 90 days, dietary La produced a reduction in plasma P in normal rats (N + La) [45 days: 3.15 +/- 0.35 vs. normal control (NC) 4.41 +/- 0.15 mg/dL, P < 0.01; 90 days: 3.20 +/- 0.30 vs. 4.09 +/- 0.15 mg/dL, P < 0.05], but not at 110 days. Plasma P was initially lower (45 days) in both groups of La-treated rats (U + La: 3.47 +/- 0.28 vs. UC: 4.91 +/- 0.27 mg/dL, P < 0.01), but was not at 90 and 110 days. Whole blood La content was not increased in rats fed the La diet and is, therefore, not a good indicator of the La content of tissue. La was increased in kidney, femur, and especially liver in normal and uremic rats fed the La diet. Uremia markedly enhanced tissue accumulation of La (liver, 110 days: N + La: 849 +/- 152 vs. U + La: 2676 +/- 479 ng/g wet wt, P < 0.01), which increased in a time-dependent manner. The increase in La in the liver of normal rats was 44-fold compared to control and 98-fold in the liver of uremic rats compared to uremic control.
CONCLUSION: La accumulates in tissues, most strikingly in the liver, and renal failure accelerates the accumulation. While this was a relatively short-term study, La accumulation increased in a time-dependent manner. The effect of long-term La treatment on patients with chronic renal insufficiency needs to be evaluated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16316357     DOI: 10.1111/j.1523-1755.2005.00753.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  23 in total

Review 1.  In situ imaging of metals in cells and tissues.

Authors:  Reagan McRae; Pritha Bagchi; S Sumalekshmy; Christoph J Fahrni
Journal:  Chem Rev       Date:  2009-10       Impact factor: 60.622

Review 2.  Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.

Authors:  Katherine Wesseling-Perry; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2013-02-05       Impact factor: 3.714

Review 3.  Controversies in the Management of Secondary Hyperparathyroidism in Chronic Kidney Disease.

Authors:  Ezequiel Bellorin-Font; George Vasquez-Rios; Kevin J Martin
Journal:  Curr Osteoporos Rep       Date:  2019-10       Impact factor: 5.096

4.  Extended release nicotinic acid - a novel oral agent for phosphate control.

Authors:  Krishnaswamy Sampathkumar; Manickam Selvam; Yesudas Santhakumari Sooraj; Sankaran Gowthaman; Rajappan Nair Prabha Ajeshkumar
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

Review 5.  Hyperphosphataemia: treatment options.

Authors:  Fabio Malberti
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

6.  Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment.

Authors:  Alastair J Hutchison; M Edwina Barnett; Rolfdieter Krause; Jonathan T C Kwan; Ghodrat A Siami
Journal:  Nephron Clin Pract       Date:  2008-07-31

7.  Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.

Authors:  Stuart M Sprague; Hanna Abboud; Ping Qiu; Matthew Dauphin; Pinggao Zhang; William Finn
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-03       Impact factor: 8.237

Review 8.  Clinical pharmacokinetics of the phosphate binder lanthanum carbonate.

Authors:  Stephen J P Damment; Michael Pennick
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

9.  A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate.

Authors:  Felix Bronner; Boris M Slepchenko; Michael Pennick; Stephen J P Damment
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 10.  Mineral metabolism and bone abnormalities in children with chronic renal failure.

Authors:  Cheryl P Sanchez
Journal:  Rev Endocr Metab Disord       Date:  2008-01-04       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.